Thomas Jefferson University

Jefferson Digital Commons
Department of Dermatology and Cutaneous
Biology Faculty Papers

Department of Dermatology and Cutaneous
Biology

10-1-2013

Chemokine-enhanced DNA vaccination in cancer immunotherapy.
Olga Igoucheva
Thomas Jefferson University

Rebecca Jonas
Thomas Jefferson University

Vitali Alexeev
Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/dcbfp
Part of the Medicine and Health Sciences Commons

Let us know how access to this document benefits you
Recommended Citation
Igoucheva, Olga; Jonas, Rebecca; and Alexeev, Vitali, "Chemokine-enhanced DNA vaccination in
cancer immunotherapy." (2013). Department of Dermatology and Cutaneous Biology Faculty
Papers. Paper 32.
https://jdc.jefferson.edu/dcbfp/32
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Dermatology and Cutaneous Biology Faculty Papers by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Author’s View

Paper Type

OncoImmunology 2:10, e26092; October 2013; © 2013 Landes Bioscience

Chemokine-enhanced DNA vaccination
in cancer immunotherapy
Olga Igoucheva, Rebecca Jonas, and Vitali Alexeev*
Department of Dermatology and Cutaneous Biology; Jefferson Medical College; Thomas Jefferson University; Philadelphia, PA USA

Keywords: chemokines, intratumoral vaccination, DNA vaccine, intradermal vaccination,
leukocyte recruitment, therapeutic vaccine

We have demonstrated that priming of intratumoral and intradermal vaccination sites with chemokines enhances
cytotoxic immune response against established neoplasms. Additional insights into the molecular mechanisms that
underlie these findings and the optimization of such an approach may lead to the development of cost-effective and
generic immunotherapeutic regimens against cancer.

During the past decade, immunotherapy has emerged as a powerful modality to
treat aggressive neoplasmsfor which a few
(if any) curative treatment modalities are
currently available. Cell-based immunotherapies, including the adoptive transfer
of tumor-infiltrating lymphocytes, dendritic cell (DC)-based vaccines and T cells
expressing recombinant tumor-specific
T-cell receptors (TCRs) or chimeric antigen receptors (CARs), showed promising
results in both pre-clinical and clinical
settings. Nevertheless, the widespread
application of these strategies to treat cancer is hindered by several factors.1 Along
similar lines, the administration of cytotoxic T lymphocyte-associated protein 4
(CTLA4)-targeting antibodies (such as
Ipilimumab) to patients with advanced
melanoma appears to be particularly
effective in the elicitation of tumor-specific immune responses. However, severe
adverse events related to the unspecific
activation of T cells at the systemic level
(and hence to the elicitation of autoimmune reactions) remain a barrier to the
widespread application of this immunotherapeutic regimen.2 Active vaccination
protocols based on tumor-associated antigens, including peptide- and DNA-based
vaccines, have also been tested in different pre-clinical and clinical settings.3

Although these approaches offer multiple
advantages and have been associated with
antineoplastic activity in pre-clinical
settings, the lack of efficacy in clinical
scenarios offsets the advantages of peptide- and DNA-based anticancer vaccines.
Hence, there is an unmet need to improve
these approaches to achieve adequate activation of tumor-specific immunity and
clinically significant outcomes.
Multiple studies demonstrated that
recruitment of different subsets of leukocytes to neoplastic lesions facilitates
recognition and elimination of malignant lesions. As we had previously
observed that elevated intratumoral levels of a secondary lymphoid chemokine,
CCL21effectively recruit T cells to the
deep recesses of melanoma mass, hence
boosting tumor elimination,4 we hypothesized that altering chemotactic gradients
within established tumors would improve
the therapeutic efficacy of anticancer vaccines. Consistently, we recently reported a
significantly greater tumor growth inhibition in CCL21-primed tumors following
DNA vaccination (Fig. 1A).5 This vaccination protocol resulted in the regression
of the pre-established melanomas associated with generation and expansion of the
intratumoral antigen (Ag)-specific cytotoxic T cells (CTL) (Fig. 1A).

Two distinct components of this immunotherapeutic regimen favorably influenced its outcome: the composition of the
DNA-based vaccine and the priming of
neoplastic lesions with chemokines. In our
hands, administration of a fusion protein
containing the pan DR epitope (PADRE),
which enhances activation of helper, effector and memory CD8 + T cells in mice
and humans,6,7 was critical for the activation of tumor-specific immune response.
On the other hand, priming of neoplastic
lesions with selected chemokines, namely,
CCL20 and CCL21 (alone or in combination), led to somehow contrasting results.
Indeed, while the expression of CCL20
was expected to recruit immature DCs
and promote both antigen uptake and activation of tumor-specific T cells, elevated
levels of this chemokine led to the recruitment of regulatory T cells, which inhibited vaccine-elicited immune response.
On the contrary, priming of melanoma
lesions with CCL21 alone resulted in the
activation of superior melanoma-specific
immune response. Although we and others have previously demonstrated that
a permanent intratumoral gradient of
CCL21 facilitates recognition of malignant cells by the immune system,4 our
recent findings demonstrated that even
a transient gradient of this chemokine
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Figure 1. Intratumoral and intradermal chemokine-enhanced DNA-based anticancer vaccination. (1) Priming of intratumoral (A) and intradermal
(B) vaccination sites with chemokines. (2) Chemokine-mediated recruitment of T cells alone (A) or accompanied by immature antigen-presenting cells
(APCs) (B). (3) Administration of DNA-based vaccines into chemokine-primed tissues, leading to enforced antigen expression by immature APCs, APC
maturation, extranodal antigen presentation via MHC class I mechanism , and T-cell activation. (4) Immediate recognition of target (cancer) cells by
activated antigen-specific cytotoxic T lymphocytes (CTLs) and CTL expansion (A), or emigration of activated CTLs from the skin to antigen-expressing
neoplastic lesions and relocation of vaccinated APCs to draining lymph nodes (LNs) and intranodal T-cell activation (B). (5) Killing of antigen-expressing
target cells by activated CTLs.

established prior to DNA vaccination
favors the accumulation, activation and
expansion of tumor-specific T cells.5 This
is consistent with previous data demonstrating that CCL21 can promote the
clonal expansion of T cells.8 Thus, our
data clearly demonstrate the efficacy of
priming malignant lesions with specific
chemokines prior to the administration
of a therapeutic DNAanticancer vaccine.
The optimization of this approach is likely
to result in the development of a generic
and cost-effective immunotherapeutic
regimen for the treatment of unresectable
(metastatic) tumors.
Currently, DNA-based anticancer vaccines are most commonly administered
via the intramuscular route, a setting in
which multinucleated, elongated muscle
cells express target antigens to high levels,
favoring antigen uptake and cross-presentation by intramuscular DCs. On the
contrary, the intradermal route allows for
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direct antigen presentation via MHC class
I mechanism by DNA-transfected cutaneous antigen-presenting cells (APCs),
including Langerhans cells and DCs.3 We
therefore hypothesized that chemokinemediated recruitment of immature DCs to
the vaccine administration site may favor
direct antigen presentation to T cells by
vaccinated DCs. We werealso convinced
that the concurrent recruitment of T cells
may further promote antigen presentation
at the vaccination site. In support of these
notions, we have recently demonstrated
that the simultaneous recruitment of DCs
and T cells to the skin prior to DNA vaccination, allows for extranodal antigen
presentation via MHC class I molecules,
T-cell activation, expansion, and antigenspecific cytotoxic immune response in
both prophylactic and therapeutic settings
(Fig. 1B).
In summary, further optimization of
the priming procedures is likely to allow
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for the efficient recruitment of immature DCs and naïve T cells to the cutaneous tissue, possibly resulting in the
formation of transient lymph node-like
structures similar to those observed in
mucosal tissues,9,10 or for the intratumoral
accumulation of T cells, 2 are expected
to improve the efficacy of therapeutic
DNA-based anticancer vaccines. It is also
plausible that optimizing the composition of DNA-based vaccines, for instance
by including various immunostimulatory
epitopes or interferon-responsive factors,
and/or administering them in the context of CTLA4 inhibition would promote
the DC-mediated activation of tumorspecific CTLs and hence the elicitation
of therapeutically relevant tumor-specific
immune response.
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